Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial
Nutrition Journal - 2024
Tóm tắt
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global metabolic problem which can lead to irreversible liver fibrosis. It has been shown that vitamin D and its receptors contribute to fibrogenic pathways in the liver. However, the effect of vitamin D supplementation on liver fibrosis related factors have not been examined. This double blinded placebo controlled clinical trial was designed to investigate the effects on vitamin D supplementation on serum levels of VDR, fibrogenic factors and fibrogenic MicroRNAs in MASLD patients. Forty six MASLD patients after block matching for sex and BMI were randomly assigned to receive 4000 IU/d vitamin D or placebo for 12 weeks. Weight, height and waist circumference were measured. Serum fibrogenic microRNAs, laminin, collagen type IV, hyaluronic acid, vitamin D, VDR, PTH, blood fasting glucose, serum fasting insulin, lipid profile, ALT and AST were determined at the baseline and at the end of the trial. Insulin resistance and insulin sensitivity were calculated using the HOMA-IR and QUICKI equation. Supplementation with vitamin D for 12 weeks led to the significant increases in serum 25(OH) vitamin D, VDR and HDL-C compared to placebo (P < 0.001, P = 0.008 and P < 0.001). There were significant decreases in ALT, AST, FBS and LDL-C levels in the vitamin D group as compared to the placebo (P < 0.05). Laminin and hyaluronic acid concentrations were significantly decreased in the vitamin D group as compared to the placebo group, by -10.6 and − 28.7 ng/mL, respectively. Supplementation with vitamin D for 12 weeks resulted in a significant lower MiR-21 and MiR-122 gene expressions compared to the placebo group (P = 0.01 and P < 0.001, respectively). As the first randomized controlled trial on the effect of vitamin D supplementation on serum levels of VDR, fibrogenic factors and fibrogenic MicroRNAs in MASLD patients, we found a significant reduction in some liver fibrogenic factors, in liver transaminases and corresponding changes in some fibrosis-related MiRs and some metabolic factors. Further clinical trials with larger sample sizes and direct measures of liver fibrosis are needed to confirm these findings. (available at:
http://www.irct.ir
, identifier: IRCT201405251485N13), Registration date: 14-03-2017.
Từ khóa
Tài liệu tham khảo
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–24.
Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-Associated fatty liver Disease (MAFLD): an update. Nutrients. 2020;12(11):3302.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver Disease (NAFLD) Pathogenesis and Natural products for Prevention and Treatment. Int J Mol Sci. 2022;23(24):15489.
Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875.
Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, Fu J. Role of Nutrition in the Pathogenesis and Prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019;15(2):265–76.
Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Al Nahdi N, Younossi MZ. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol. 2020;26(25):3528–41.
Bradford V, Dillon J, Miller M. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. Hepat Med. 2014;6:1–10.
Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–83.
Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103.
Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. Biomed Res Int. 2020;2020:4020249.
Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38(3):246–54.
Iruzubieta P, Terán Á, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014;6(12):901–15.
Reid IR. What diseases are causally linked to vitamin D deficiency? Arch Dis Child. 2016;101(2):185–9.
Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: molecular mechanisms and clinical studies. Biomed Pharmacother. 2019;109:1351–60.
Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol. 2015;7(2):226–34.
Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver Disease and Hepatocellular Carcinoma. J Clin Med. 2016;5(3):30.
Rotllan N, Fernández-Hernando C. MicroRNA Regulation of Cholesterol Metabolism. Cholesterol. 2012; 2010:1–8.
Liu CH, Ampuero J, Gil-Gomez A, Montero-Vallejo R, Rojas A, Munoz-Hernandez R. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2018;69(6):1335–48.
Sharifi N, Amani R, Hajiani E, Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47(1):70–80.
Barchetta I, Ben MD, Angelico F, Di Martino M, Fraioli A, La Torre G. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92.
Taghavei A, Akha O, Mouodi M, Fakheri HT, Kashi Z, Maleki I, Mohammadpour R. Effect of vitamin D supplementation on patients with non-alcoholic fatty liver disease (NAFLD). Acta Med Mediterranea. 2018;34:415–22.
Dabbaghmanesh MH, Danafar F, Eshraghian A, Omrani GR. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: a randomized double blind placebo controlled trial. Diabetes Metab Syndr. 2018;12(4):513–7.
Ebrahimpour-Koujan S, Sohrabpour AA, Foroughi F, Alvandi E, Esmaillzadeh A. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial. Trials. 2019;20(1):153.
Saghaei M. Random allocation software for parallel group randomized trials. BMC 4. 2004; (26);1–6.
Płudowski P, Kos-Kudła B, Walczak M, Fal A, Zozulińska-Ziółkiewicz D, Sieroszewski P. Guidelines for preventing and treating vitamin D Deficiency: a 2023 update in Poland. Nutrients. 2023;15(3):695.
Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010;47(2):165–9.
Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C. 2011 Compendium of Physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43(8):1575–81.
Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71–85.
Zanello LP, Norman AW. Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci U S A. 2004;101(6):1589–94.
Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol. 2011;35(4):295–302.
Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153(3):601–13.
Canbay AE, Beilfuss A, Sydor S, Sowa JP, Seydel S, Syn WK. & Modulation of fibrogenic factors in hepatic stellate cells by Vitamin D and reduction of vitamin D in NAFLD patients: implications for NAFLD therapy. Z Gastroenterol 2010; 48 - V38.
Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab. 2013;98(2):E298–303.
Han H, Cui M, You X, Chen M, Piao X, Jin G. A role of 1,25(OH)2D3 supplementation in rats with nonalcoholic steatohepatitis induced by choline-deficient diet. Nutr Metab Cardiovasc Dis. 2015;25(6):556–61.
Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60(6):619–26.
Jiang Y, Cheng DW, Crook ED, Singh LP. Transforming growth factor-beta1 regulation of laminin gamma1 and fibronectin expression and survival of mouse mesangial cells. Mol Cell Biochem. 2005;278(1–2):165–75.
Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49(3):302–15.
Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol. 2009;200(2):207–21.
Jorde R, Svartberg J, Joakimsen RM, Coucheron DH. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12 months. BMC Res Notes. 2012;5:245.
Pastuszak-Lewandoska D, Domańska-Senderowska D, Kiszałkiewicz J, Szmigielska P, Snochowska A, Ratkowski W. & Expression levels of selected cytokines and microRNAs in response to vitamin D supplementation in ultra-marathon runners. Eur J Sport Sci. 2019:1–26.
Cui C, Cui Q. The relationship of human tissue microRNAs with those from body fluids. Sci Rep. 2020;10:5644.
Sohel Mh. Extracellular/Circulating MicroRNAs: Release mechanisms, functions and challenges. Achievements in the Life Sciences. 2016;10(2):175–86.
Pirola CJ, Gianotti FT, Castaño GO, Mallardi P, MartinoJS, Gonzalez Lopez Ledesma MM. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–12.
Sriphoosanaphan S, Thanapirom K, Kerr SJ, Suksawatamnuay S, Thaimai P, Sittisomwong S. Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial. PeerJ. 2021;9:e10709.
Zanko VL, Domislovic V, Trkulja V, Krznaric-Zrnic I, Turk-Wensveen T, Krznaric Z. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2020;22(11):2097–106.
Geier A, Eichinger M, Stirnimann G, Semela D, Tay F, Seifert B. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scand J Gastroenterol. 2018;53(9):1114–20.
Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. Nefrologia. 2015;35(1):28–41.
Mohseni H, Hosseini SA, Amani R, Ekrami A, Ahmadzadeh A, Latifi SM. Circulating 25-Hydroxy vitamin D relative to vitamin D receptor polymorphism after vitamin D3 supplementation in breast Cancer women: a Randomized, double-blind controlled clinical trial. Asian Pac J Cancer Prev. 2017;18(7):1953–9.
Hosseini SM, Aliashrafi S, Ebrahimi-Mameghani M. The Effect of a single intramuscular injection of Cholecalciferol on the Serum Levels of Vitamin D, Adiponectin, insulin resistance, and liver function in women with non-alcoholic fatty liver Disease (NAFLD): a Randomized, Controlled Clinical Trial. Iran Red Crescent Med J. 2018;20(10):e60746.
Papapostoli I, Lammert F, Stokes CS. Effect of short-term vitamin D correction on Hepatic Steatosis as quantified by controlled attenuation parameter (CAP). J Gastrointestin Liver Dis. 2016;25(2):175–81.
Kim H, Chandler P, Ng K, Manson JE, Giovannucci E. Obesity and efficacy of vitamin D 3 supplementation in healthy black adults. Cancer Causes Control. 2020;31(4):303–7.
Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with nonalcoholic fatty liver Disease have a low response rate to Vitamin D Supplementation. J Nutr. 2017;147(10):1938–46.
Lorvand Amiri H, Agah S, Tolouei Azar J, Hosseini S, Shidfar F, Mousavi SN. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial. Clin Nutr. 2017;36(6):1490–7.
Sakpal M, Satsangi S, Mehta M, Duseja A, Bhadada S, Das A. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial. JGH Open. 2017;1(2):62–7.
Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Ramezani-Jolfaie N, Joukar F. The efficacy of vitamin D supplementation against nonalcoholic fatty liver disease: a Meta-analysis. J Diet Suppl. 2020;17(4):467–85.
Tobias DK, Luttmann-Gibson H, Mora S, Danik J, Bubes V, Copeland T. Association of Body Weight with response to vitamin D supplementation and metabolism. JAMA Netw Open. 2023;6(1):e2250681.
Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85:6–18.